Sensorium Therapeutics names new chief scientific officer
19 January 2023 -

Sensorium Therapeutics, a California-based biotechnology company leveraging medicinal chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health, announced on Wednesday that it has named Jeffrey M Brown, PhD, MBA as its new chief scientific officer.

In the new role, Dr Brown will manage the progress of the company's initial candidate, SENS-01, which is being developed as a rapid-acting and well-tolerated therapeutic for subjects with anxiety and depression, and its Biodynamic Discovery Platform (BDP), a drug discovery engine that rapidly identifies, synthesises, and improves target molecules as novel therapeutics.

Dr Brown has served as vice president and head of Preclinical Research at Deep Genomics. He has held leadership positions at Voyager Therapeutics, Wave Life Sciences, and Alexion Pharmaceuticals. He has spent more than two decades at Amgen, Pfizer, and Bristol-Myers Squibb.